Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year High - Here's What Happened

Key Points

• Halozyme shares reached a new 52-week high, trading as high as $119.21 and closing around $116.82, up sharply from the prior close of $109.62.
• The company reported strong quarterly results, with EPS of $2.28 versus estimates of $1.79 and revenue of $481 million, up 47.7% year over year. Management provided fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and an average price target of $96.50, although insiders sold approximately $13.5 million of stock over the past three months.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $119.21 and last traded at $116.82, with a volume of 3,768,940 shares. The stock had previously closed at $109.62.

Wall Street Analysts Forecast Growth

HALO has been the topic of several recent analyst reports. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, August 31st. Citizens Jmp upped their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $96.50.

Halozyme Therapeutics Stock Performance

The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The business has a 50-day moving average of $107.97 and a 200-day moving average of $84.24. The company has a market capitalization of $13.26 billion, a P/E ratio of 22.24, a P/E/G ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the firm's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the completion of the sale, the director owned 53,609 shares in the company, valued at $5,818,720.86. This represents a 8.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock worth $13,538,046 over the last three months. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Mather Group LLC. lifted its position in shares of Halozyme Therapeutics by 48.9% in the third quarter. Mather Group LLC. now owns 414 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 136 shares in the last quarter. Signal Advisors Wealth LLC bought a new position in Halozyme Therapeutics in the third quarter valued at approximately $850,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $232,000. Cooper Investors PTY Ltd. increased its holdings in Halozyme Therapeutics by 19.8% during the third quarter. Cooper Investors PTY Ltd. now owns 65,933 shares of the biopharmaceutical company's stock worth $7,279,000 after buying an additional 10,910 shares during the last quarter. Finally, NorthCrest Asset Manangement LLC lifted its stake in Halozyme Therapeutics by 27.7% in the third quarter. NorthCrest Asset Manangement LLC now owns 57,661 shares of the biopharmaceutical company's stock valued at $6,333,000 after acquiring an additional 12,511 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.